AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 9494881 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined weight and cycle training
Number of subjects: 23
Study 9494881 — intervention group
Group type: COMPARATOR
Intervention: Cycle training
Number of subjects: 23
Study 7531487 — intervention group
Group type: EXPERIMENTAL
Intervention: Vinorelbine (30 mg/m2 i.v. bolus weekly)
Number of subjects: 24
Study 3062535 — intervention group
Group type: EXPERIMENTAL
Intervention: Nd:YAG laser treatment
Number of subjects: 43
Study 3062535 — intervention group
Group type: COMPARATOR
Intervention: Argon laser treatment
Number of subjects: 43
Study 29580746 — intervention group
Group type: EXPERIMENTAL
Intervention: Riociguat
Number of subjects: 237
Study 29580746 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 237
Study 26928845 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal testosterone gel daily for 14 weeks
Number of subjects: 64
Study 26928845 — intervention group
Group type: COMPARATOR
Intervention: Placebo gel daily for 14 weeks
Number of subjects: 64
Study 26928845 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal testosterone gel
Number of subjects: 64
Study 25344483 — intervention group
Group type: EXPERIMENTAL
Intervention: e-learning
Number of subjects: 183
Study 25344483 — intervention group
Group type: EXPERIMENTAL
Intervention: classroom teaching
Number of subjects: 183
Study 23118021 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose MDMA (25 mg, plus 12.5 mg supplemental dose)
Number of subjects: 12
Study 23118021 — intervention group
Group type: EXPERIMENTAL
Intervention: Full-dose MDMA (125 mg, plus 62.5 mg supplemental dose)
Number of subjects: 12
Study 23118021 — intervention group
Group type: EXPERIMENTAL
Intervention: Three MDMA sessions
Number of subjects: 12
Study 23118021 — intervention group
Group type: COMPARATOR
Intervention: Control group (active-placebo)
Number of subjects: 12
Study 20844457 — intervention group
Group type: EXPERIMENTAL
Intervention: Eccentric-concentric load of 60-40 kg (40 kg concentric with additional 20 kg eccentric)
Number of subjects: 14
Study 20844457 — intervention group
Group type: EXPERIMENTAL
Intervention: Eccentric-concentric load of 70-40 kg (40 kg concentric with additional 30 kg eccentric)
Number of subjects: 14
Study 20844457 — intervention group
Group type: EXPERIMENTAL
Intervention: Eccentric-concentric load of 80-40 kg (40 kg concentric with additional 40 kg eccentric)
Number of subjects: 14
Study 20844457 — intervention group
Group type: COMPARATOR
Intervention: Eccentric-concentric load of 40-40 kg (equated load condition)
Number of subjects: 14
Study 19043158 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioural therapy (CBT)
Number of subjects: 0
Study 19043158 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study 16848349 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A (normal radiographic and scintigraphic examinations)
Number of subjects: 80
Study 16848349 — intervention group
Group type: EXPERIMENTAL
Intervention: Group B (diffusely increased uptake)
Number of subjects: 80
Study 16848349 — intervention group
Group type: EXPERIMENTAL
Intervention: Group C (pathology revealed by radiography and scintigraphy)
Number of subjects: 80
Study 16848349 — intervention group
Group type: COMPARATOR
Intervention: Group D (knee-healthy controls)
Number of subjects: 80
Study 12839713 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunoglobulin concentrate-supplemented infant formula
Number of subjects: 125
Study 12839713 — intervention group
Group type: COMPARATOR
Intervention: Control formula (non-supplemented)
Number of subjects: 125
Study 10440423 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel 75 mg in fasting state
Number of subjects: 24
Study 10440423 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel 75 mg in fed state
Number of subjects: 24
Study 10440423 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel 75 mg with antacid (Maalox 2 x 400 mg tablets 1 hour before dosing)
Number of subjects: 24
Study 10440423 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel 75 mg without antacid
Number of subjects: 24
Study 8558205 — intervention group
Group type: EXPERIMENTAL
Intervention: Buthionine sulfoximine (BSO) 1.5 to 17 g/m2 intravenously every 12 hours for six doses, followed by melphalan (L-PAM) 15 mg/m2 intravenously 1 hour after the fifth dose of BSO in the second cycle.
Number of subjects: 41
Study 8558205 — intervention group
Group type: EXPERIMENTAL
Intervention: Buthionine sulfoximine (BSO) at doses >= 13 g/m2.
Number of subjects: 41
Study 8558205 — intervention group
Group type: EXPERIMENTAL
Intervention: Buthionine sulfoximine (BSO) at various doses.
Number of subjects: 41
Study 1805152 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg vitamin K1 intramuscularly
Number of subjects: 12
Study 1805152 — intervention group
Group type: COMPARATOR
Intervention: Control group (no vitamin K1)
Number of subjects: 12
Study 6125195 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg pindolol
Number of subjects: 30
Study 6125195 — intervention group
Group type: COMPARATOR
Intervention: 100 mg metoprolol
Number of subjects: 30
Study 31246882 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral Therapy for Insomnia (CBT-I) for 6 weeks
Number of subjects: 24
Study 31246882 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral Therapy for Insomnia (CBT-I)
Number of subjects: 24
Study 31246882 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (control)
Number of subjects: 24
Study 29493402 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol/fluticasone Easyhaler (two inhalations of 50/500 μg/inhalation strength)
Number of subjects: 65
Study 29493402 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol/fluticasone Easyhaler
Number of subjects: 65
Study 29493402 — intervention group
Group type: COMPARATOR
Intervention: Seretide® Diskus® DPI (reference product)
Number of subjects: 65
Study 25892407 — intervention group
Group type: EXPERIMENTAL
Intervention: No-sedation
Number of subjects: 140
Study 25892407 — intervention group
Group type: COMPARATOR
Intervention: Sedation with daily wake up
Number of subjects: 140
Study 24923533 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive Geriatric Assessment (CGA) conducted by a geriatrician before cancer treatment, participation of the same geriatrician in cancer treatment selection, a standardised geriatric therapeutic intervention designed by the same geriatrician, and geriatric follow-up for 24 months.
Number of subjects: 704
Study 24923533 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive Geriatric Assessment (CGA)
Number of subjects: 704
Study 22934526 — intervention group
Group type: EXPERIMENTAL
Intervention: Shengjing prescription
Number of subjects: 120
Study 22934526 — intervention group
Group type: COMPARATOR
Intervention: Vitamin E (Control)
Number of subjects: 120
Study 20231191 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical decision support (CDS) embedded in the electronic health record (EHR)
Number of subjects: 12
Study 18754979 — intervention group
Group type: EXPERIMENTAL
Intervention: Parish Nurse Intervention Program (n=49)
Number of subjects: 100
Study 18754979 — intervention group
Group type: COMPARATOR
Intervention: Care As Usual (n=51)
Number of subjects: 100
Study 16033354 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized vitamin B12
Number of subjects: 23
Study 16033354 — intervention group
Group type: COMPARATOR
Intervention: 0.02% vitamin B12 eye drops
Number of subjects: 23
Study 16033354 — intervention group
Group type: COMPARATOR
Intervention: Control group (no medication)
Number of subjects: 23
Study 15258534 — intervention group
Group type: EXPERIMENTAL
Intervention: Assisted hatching (mechanical, chemical, laser beam, piezoelectric method)
Number of subjects: 0
Study 15258534 — intervention group
Group type: EXPERIMENTAL
Intervention: Assisted hatching
Number of subjects: 0
Study 11598983 — intervention group
Group type: EXPERIMENTAL
Intervention: Interventions included education and voluntary medical surveillance in 1994; substitution of low protein, 'powder-free' NRL gloves for non-sterile powdered gloves in 1995; replacement of powdered sterile NRL gloves by lower protein, 'powder-free' NRL gloves in 1997.
Number of subjects: 60
Study 11598983 — intervention group
Group type: EXPERIMENTAL
Intervention: Glove changes and latex policies instituted by hospitals.
Number of subjects: 60
Study 9065537 — intervention group
Group type: EXPERIMENTAL
Intervention: NSAID use (2 or more years)
Number of subjects: 1686
Study 9065537 — intervention group
Group type: COMPARATOR
Intervention: NSAID use (less than 2 years)
Number of subjects: 1686
Study 9065537 — intervention group
Group type: COMPARATOR
Intervention: Aspirin use
Number of subjects: 1686
Study 9065537 — intervention group
Group type: COMPARATOR
Intervention: Acetaminophen use
Number of subjects: 1686
Study 8145097 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher potency pancreatic enzyme preparations
Number of subjects: 0
Study 8145097 — intervention group
Group type: EXPERIMENTAL
Intervention: Pancreatic enzyme preparations
Number of subjects: 0
Study 8145097 — intervention group
Group type: EXPERIMENTAL
Intervention: Fecal energy loss
Number of subjects: 0
Study 8145097 — intervention group
Group type: EXPERIMENTAL
Intervention: In vitro enzyme potency
Number of subjects: 0
Study 8145097 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher potency preparations
Number of subjects: 0
Study 3463271 — intervention group
Group type: EXPERIMENTAL
Intervention: Spar-Cal
Number of subjects: 10
Study 3463271 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium Sandoz
Number of subjects: 10
Study 3463271 — intervention group
Group type: EXPERIMENTAL
Intervention: Os-Cal
Number of subjects: 10
Study 3463271 — intervention group
Group type: EXPERIMENTAL
Intervention: Ossopan
Number of subjects: 10
Study 3463271 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium supplements (1 gram of elemental calcium)
Number of subjects: 10
Study 30290615 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed-loop target-controlled infusion of propofol and remifentanil
Number of subjects: 204
Study 30290615 — intervention group
Group type: COMPARATOR
Intervention: Manual target-controlled infusion of propofol and remifentanil
Number of subjects: 204
Study 26929604 — intervention group
Group type: EXPERIMENTAL
Intervention: Xuanbai Chengqi decoction
Number of subjects: 53
Study 26929604 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment and lung-protective ventilation strategy
Number of subjects: 53
Study 23858525 — intervention group
Group type: EXPERIMENTAL
Intervention: Train‐the‐trainer programme 'Fit for Shared Decision‐Making'
Number of subjects: 402
Study 23858525 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly defined in the abstract)
Number of subjects: 402
Study 22839709 — intervention group
Group type: EXPERIMENTAL
Intervention: ω-3 polyunsaturated fatty acids (PUFA) 1 g/day for 6 months
Number of subjects: 80
Study 22839709 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard antiarrhythmic therapy without ω-3 PUFA)
Number of subjects: 80
Study 20346242 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination DMARD therapy (COMBI) starting with sulfasalazine, methotrexate, hydroxychloroquine, and prednisolone
Number of subjects: 195
Study 20346242 — intervention group
Group type: COMPARATOR
Intervention: Monotherapy (SINGLE) initially with sulfasalazine, with or without prednisolone
Number of subjects: 195
Study 19067892 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC, 30-45 mg/kg/d)
Number of subjects: 10
Study 19067892 — intervention group
Group type: COMPARATOR
Intervention: L-alanine
Number of subjects: 10
Study 16188807 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulization of 0.25 mg dexamethasone every 6 hours (group 1)
Number of subjects: 61
Study 16188807 — intervention group
Group type: COMPARATOR
Intervention: Nebulization of 0.9% saline (group 2)
Number of subjects: 61
Study 16188807 — intervention group
Group type: EXPERIMENTAL
Intervention: Subgroup of prematurely born children in group 1
Number of subjects: 61
Study 16188807 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (group 1 and group 2)
Number of subjects: 61
Study 14519708 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen plus progestin (0.625 mg conjugated equine estrogens plus 2.5 mg medroxyprogesterone acetate)
Number of subjects: 16608
Study 14519708 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16608
Study 10561249 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen (TAM) 20 mg/d for 4 years plus Epirubicin (EPI) 50 mg/m² intravenously on days 1 and 8 every 4 weeks for six cycles
Number of subjects: 604
Study 10561249 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen (TAM) 20 mg/d for 4 years
Number of subjects: 604
Study 8751014 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoprofen 50 mg
Number of subjects: 18
Study 8751014 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoprofen 100 mg
Number of subjects: 18
Study 8751014 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoprofen 150 mg
Number of subjects: 18
Study 8751014 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 2164193 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin/Vepesid
Number of subjects: 150
Study 2164193 — intervention group
Group type: COMPARATOR
Intervention: Endoxan/Vepesid
Number of subjects: 150
Study 400734 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous administration of regular insulin
Number of subjects: 0
Study 400734 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30644283 — intervention group
Group type: EXPERIMENTAL
Intervention: WALANT (Wide Awake Local Anaesthesia Without Tourniquet)
Number of subjects: 60
Study 30644283 — intervention group
Group type: COMPARATOR
Intervention: Loco-regional anaesthesia with tourniquet
Number of subjects: 60
Study 30644283 — intervention group
Group type: EXPERIMENTAL
Intervention: WALANT
Number of subjects: 60
Study 27052787 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean diet supplemented with nuts and pharmacological treatment
Number of subjects: 50
Study 24931748 — intervention group
Group type: EXPERIMENTAL
Intervention: Homeopathic treatment plus usual care
Number of subjects: 0
Study 24931748 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study 24931748 — intervention group
Group type: EXPERIMENTAL
Intervention: Supportive listening plus usual care
Number of subjects: 0
Study 22804250 — intervention group
Group type: EXPERIMENTAL
Intervention: Dulaglutide 0.5 mg
Number of subjects: 167
Study 22804250 — intervention group
Group type: EXPERIMENTAL
Intervention: Dulaglutide 1.0 mg
Number of subjects: 167
Study 22804250 — intervention group
Group type: EXPERIMENTAL
Intervention: Dulaglutide 1.5 mg
Number of subjects: 167
Study 22804250 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 167
Study 22804250 — intervention group
Group type: EXPERIMENTAL
Intervention: Dulaglutide 0.1 mg
Number of subjects: 167
Study 22804250 — intervention group
Group type: EXPERIMENTAL
Intervention: All dulaglutide doses
Number of subjects: 167
Study 20410085 — intervention group
Group type: EXPERIMENTAL
Intervention: DAG oil (40 g/d)
Number of subjects: 26
Study 20410085 — intervention group
Group type: COMPARATOR
Intervention: Control oil (40 g/d)
Number of subjects: 26
Study 18481239 — intervention group
Group type: EXPERIMENTAL
Intervention: Resection (n = 20)
Number of subjects: 80
Study 18481239 — intervention group
Group type: EXPERIMENTAL
Intervention: Transection (n = 20)
Number of subjects: 80
Study 18481239 — intervention group
Group type: EXPERIMENTAL
Intervention: Ablation (n = 20)
Number of subjects: 80
Study 18481239 — intervention group
Group type: EXPERIMENTAL
Intervention: Clipping (n = 20)
Number of subjects: 80
Study 18481239 — intervention group
Group type: COMPARATOR
Intervention: All techniques
Number of subjects: 80
Study 16393757 — intervention group
Group type: EXPERIMENTAL
Intervention: Eye movement measures for reading speed
Number of subjects: 1
Study 16393757 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurocognitive assessment
Number of subjects: 1
Study 14686231 — intervention group
Group type: EXPERIMENTAL
Intervention: Universal prophylaxis
Number of subjects: 0
Study 14686231 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective prophylaxis
Number of subjects: 0
Study 14686231 — intervention group
Group type: EXPERIMENTAL
Intervention: Preemptive therapy
Number of subjects: 0
Study 14686231 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment of active disease
Number of subjects: 0
Study 14686231 — intervention group
Group type: EXPERIMENTAL
Intervention: CMV immune globulin i.v.
Number of subjects: 0
Study 14686231 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ganciclovir
Number of subjects: 0
Study 14686231 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral acyclovir
Number of subjects: 0
Study 14686231 — intervention group
Group type: EXPERIMENTAL
Intervention: Valacyclovir
Number of subjects: 0
Study 14686231 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ganciclovir
Number of subjects: 0
Study 14686231 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral valganciclovir
Number of subjects: 0
Study 10747210 — intervention group
Group type: COMPARATOR
Intervention: Epidural morphine 1 mg after surgery with PCA delivering morphine 0.2 mg h‐1, 0.2 mg per bolus.
Number of subjects: 60
Study 10747210 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural morphine 1 mg plus ketamine 5 mg after surgery with PCA delivering morphine 0.2 mg + ketamine 0.5 mg h‐1, morphine 0.2 mg + ketamine 0.5 mg per bolus.
Number of subjects: 60
Study 8721941 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic shoes (Podiabetes by Buratto Italy)
Number of subjects: 69
Study 8721941 — intervention group
Group type: COMPARATOR
Intervention: Own shoes (Control group)
Number of subjects: 69
Study 2406462 — intervention group
Group type: EXPERIMENTAL
Intervention: Double‐pigtail stents placed before extracorporeal shock wave lithotripsy
Number of subjects: 50
Study 2406462 — intervention group
Group type: COMPARATOR
Intervention: Control group (no stents)
Number of subjects: 50
Study 7191313 — intervention group
Group type: EXPERIMENTAL
Intervention: Acemetacin (180 mg daily in three divided doses)
Number of subjects: 40
Study 7191313 — intervention group
Group type: COMPARATOR
Intervention: Indometacin (150 mg daily in three divided doses)
Number of subjects: 40
Study 6507551 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% sodium hyaluronate (Healon) used during anterior capsulotomy and nuclear expression
Number of subjects: 181
Study 6507551 — intervention group
Group type: COMPARATOR
Intervention: No sodium hyaluronate used
Number of subjects: 181
Study 6507551 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% sodium hyaluronate (Healon) used later in the procedure
Number of subjects: 181
Study 6507551 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% sodium hyaluronate (Healon) used
Number of subjects: 181
Study 30832646 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening for mental health disorders using validated tools
Number of subjects: 1015
Study 30305073 — intervention group
Group type: EXPERIMENTAL
Intervention: 23G system
Number of subjects: 60
Study 30305073 — intervention group
Group type: COMPARATOR
Intervention: 20G system
Number of subjects: 60
Study 26692375 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebivolol
Number of subjects: 30
Study 26692375 — intervention group
Group type: COMPARATOR
Intervention: Metoprolol
Number of subjects: 30
Study 25231604 — intervention group
Group type: EXPERIMENTAL
Intervention: Real-time ultrasound guidance
Number of subjects: 50
Study 25231604 — intervention group
Group type: COMPARATOR
Intervention: Traditional anatomical landmarks
Number of subjects: 50
Study 21862446 — intervention group
Group type: EXPERIMENTAL
Intervention: Positivity motivation in social cognition
Number of subjects: 0
Study 21862446 — intervention group
Group type: EXPERIMENTAL
Intervention: Neural activation in response to social targets
Number of subjects: 0
Study 21862446 — intervention group
Group type: EXPERIMENTAL
Intervention: OFC activity
Number of subjects: 0
Study 21862446 — intervention group
Group type: EXPERIMENTAL
Intervention: Intimacy with the social target
Number of subjects: 0
Study 20096136 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual Therapy according to the Utrecht School of Manual Therapy (MTU) for six weeks
Number of subjects: 180
Study 20096136 — intervention group
Group type: COMPARATOR
Intervention: Physical Therapy (standard care, mainly active exercise therapy) for six weeks
Number of subjects: 180
Study 16859993 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 12
Study 16859993 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan
Number of subjects: 12
Study 16859993 — intervention group
Group type: COMPARATOR
Intervention: Diclofenac (both treatments)
Number of subjects: 12
Study 16053779 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol treatment
Number of subjects: 54
Study 16053779 — intervention group
Group type: COMPARATOR
Intervention: Regular treatment
Number of subjects: 54
Study 12400712 — intervention group
Group type: EXPERIMENTAL
Intervention: Human fibroblast-derived dermis (HFDD) plus saline-moistened gauze
Number of subjects: 28
Study 12400712 — intervention group
Group type: COMPARATOR
Intervention: Saline-moistened gauze alone (CT)
Number of subjects: 28
Study 10464875 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized albuterol
Number of subjects: 30
Study 10464875 — intervention group
Group type: COMPARATOR
Intervention: Nebulized normal saline (control group)
Number of subjects: 30
Study 7889634 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.1 ml/kg of 95% ethanol
Number of subjects: 12
Study 7889634 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 7889634 — intervention group
Group type: EXPERIMENTAL
Intervention: Background alcohol intake
Number of subjects: 12
Study 2198135 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal CPAP (range 2.5 to 12.5 cm H2O)
Number of subjects: 8
Study 2198135 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal oxygen (O2) at 4 LPM
Number of subjects: 8
Study 2198135 — intervention group
Group type: COMPARATOR
Intervention: Placebo (air at 4 LPM)
Number of subjects: 8
Study 347885 — intervention group
Group type: EXPERIMENTAL
Intervention: Maprotiline
Number of subjects: 95
Study 347885 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxepin
Number of subjects: 95
Study 30852915 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2% xanthan gum eye drops (group 1)
Number of subjects: 30